Pharma BD Deal Intelligence
GSK's ofatumumab bet with Genmab flopped commercially in oncology and was sold to Novartis for $1B in 2015 — only to become a genuine blockbuster (Kesimpta, $3.2B in 2024) after Novartis repositioned it for MS, meaning the value GSK paid to develop never materialized under GSK's own ownership.
Full analysis, sources & comparables →GSK and Genmab announced a co-development and commercialization agreement for ofatumumab in CD20+ B-CLL, follicular NHL and Phase II rheumatoid arthritis with…
FDA granted accelerated approval to Arzerra (ofatumumab) for fludarabine- and alemtuzumab-refractory CLL based on a 42% objective response rate in the pivotal…
Genmab retains a 25% partial interest in HuMax-TAC-ADC, an ADC combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Original ofatumumab Dec 2006; total deal up to $2.1B in 2009 amendments. Source: GSK, Genmab filings. NOTE: original signing 2006 — listing 2009 amendment iteration if applicable.
GSK's ofatumumab bet with Genmab flopped commercially in oncology and was sold to Novartis for $1B in 2015 — only to become a genuine blockbuster (Kesimpta, $3.2B in 2024) after Novartis repositioned it for MS, meaning the value GSK paid to develop never materialized under GSK's own ownership.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Genmab A/S (HuMax-TAC follow-on) (this deal) | 2009 | $102M | 34 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2009 deals · GlaxoSmithKline plc deals